Among 40 recurrent driver alterations described in breast cancer, only HER2 amplification, germline BRCA1/2 mutations, and PIK3CA mutations were given level 1A evidence as molecular targets whereas NTRK fusions and microsatellite instability (MSI) were ranked as 1C evidence. Here, ERBB2 is linked to breast carcinoma.